Cargando…

Current process and future path for health economic assessment of pharmaceuticals in France

The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommen...

Descripción completa

Detalles Bibliográficos
Autores principales: Toumi, Mondher, Rémuzat, Cécile, El Hammi, Emna, Millier, Aurélie, Aballéa, Samuel, Chouaid, Christos, Falissard, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802685/
https://www.ncbi.nlm.nih.gov/pubmed/27123173
http://dx.doi.org/10.3402/jmahp.v3.27902
_version_ 1782422772462387200
author Toumi, Mondher
Rémuzat, Cécile
El Hammi, Emna
Millier, Aurélie
Aballéa, Samuel
Chouaid, Christos
Falissard, Bruno
author_facet Toumi, Mondher
Rémuzat, Cécile
El Hammi, Emna
Millier, Aurélie
Aballéa, Samuel
Chouaid, Christos
Falissard, Bruno
author_sort Toumi, Mondher
collection PubMed
description The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommendations and health economic opinions. This article provides an in-depth description of the CEESP's structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France. It also points out the areas of uncertainty and the conflicting rules following the introduction of the health economic assessment in France. The authors also provide their personal opinion on the likely future of health economic assessment of drugs in France, including the possible merge of the CEESP and the Transparency Committee, the implementation of a French threshold, and the extension of health economic assessment to a larger number of products.
format Online
Article
Text
id pubmed-4802685
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Co-Action Publishing
record_format MEDLINE/PubMed
spelling pubmed-48026852016-04-27 Current process and future path for health economic assessment of pharmaceuticals in France Toumi, Mondher Rémuzat, Cécile El Hammi, Emna Millier, Aurélie Aballéa, Samuel Chouaid, Christos Falissard, Bruno J Mark Access Health Policy Debate Piece The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommendations and health economic opinions. This article provides an in-depth description of the CEESP's structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France. It also points out the areas of uncertainty and the conflicting rules following the introduction of the health economic assessment in France. The authors also provide their personal opinion on the likely future of health economic assessment of drugs in France, including the possible merge of the CEESP and the Transparency Committee, the implementation of a French threshold, and the extension of health economic assessment to a larger number of products. Co-Action Publishing 2015-06-04 /pmc/articles/PMC4802685/ /pubmed/27123173 http://dx.doi.org/10.3402/jmahp.v3.27902 Text en © 2015 Mondher Toumi et al. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.
spellingShingle Debate Piece
Toumi, Mondher
Rémuzat, Cécile
El Hammi, Emna
Millier, Aurélie
Aballéa, Samuel
Chouaid, Christos
Falissard, Bruno
Current process and future path for health economic assessment of pharmaceuticals in France
title Current process and future path for health economic assessment of pharmaceuticals in France
title_full Current process and future path for health economic assessment of pharmaceuticals in France
title_fullStr Current process and future path for health economic assessment of pharmaceuticals in France
title_full_unstemmed Current process and future path for health economic assessment of pharmaceuticals in France
title_short Current process and future path for health economic assessment of pharmaceuticals in France
title_sort current process and future path for health economic assessment of pharmaceuticals in france
topic Debate Piece
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802685/
https://www.ncbi.nlm.nih.gov/pubmed/27123173
http://dx.doi.org/10.3402/jmahp.v3.27902
work_keys_str_mv AT toumimondher currentprocessandfuturepathforhealtheconomicassessmentofpharmaceuticalsinfrance
AT remuzatcecile currentprocessandfuturepathforhealtheconomicassessmentofpharmaceuticalsinfrance
AT elhammiemna currentprocessandfuturepathforhealtheconomicassessmentofpharmaceuticalsinfrance
AT millieraurelie currentprocessandfuturepathforhealtheconomicassessmentofpharmaceuticalsinfrance
AT aballeasamuel currentprocessandfuturepathforhealtheconomicassessmentofpharmaceuticalsinfrance
AT chouaidchristos currentprocessandfuturepathforhealtheconomicassessmentofpharmaceuticalsinfrance
AT falissardbruno currentprocessandfuturepathforhealtheconomicassessmentofpharmaceuticalsinfrance